1SAKORAFAS GH, SAFIOLEAS M. Breast cancer surgery: an historical narrative. Part 1. From prehistoric times to Renaissance[J]. Eur J Cancer Care ( Engl), 2009,18 ( 6 ): 530- 544.
2[1]Heller W,Mazhar D,Ward R.et al.Neoadjuvant 5-fluorouracll,epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.Oncol Rep,2007,17:253-259.
3[2]Sarid D,Ron I G,Sperber F,et al.Neoadjuvant treatment with paclltaxd and epirubicin in invasive breast cancer:a phase Ⅱstudy.Clin Drug Investig,2006,26:691-701.
4[3]Fernández Morales L A,SeguíM A,Andreu X,et al.Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor,progesterone receptor,and HER-2 status.Clin Breast Cancer,2007,7:559-564.
5[4]Tiezzi D G,Andrade J M,Ribeiro silva A,et al.HER-2,p53,p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicincombination.BMC Cancer,2007,7:36.
6[5]Learn P A,Yeh I T,McNutt M,et al.HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.Cancer,2005,103:2252-2260.[6] Fernández Sánchez M,Gamboa Dominguez A,Uribe N,et al.Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanccd breast cancer.Med Oncol,2006,23:171-183.
7[7]Zhang B,Zhang Q,Zhan L,et al.Assessment of neoadjuvant chemotherapy in breast cancer patients.Zhonghua Zhong Liu Za Zhi,2006.28:867-870.
8[8]Tacca O.Penault Llorca F,Abrial C,et al.Changes in and prognostic value of hormone receptor status in a aeries of operable breast cancer patients treated with neoadjuvant chemotherapy.Oncologlst,2007,12:636-643.
9[9]Varga z,Caduff R,Pestalozzi B,et al.Stability of the HER-2 gene after primary chemotherapy in advanced breast cancer.Virchows Arch,2005,446:136-141.
10[10]Arens N,Bleyl U,Hildenbrand R,et al.HER-2/neu,p53,Ki67,and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.Virchows Arch,2005,446:489-496.
3Candlo AS,Gonzalez-Angulo AM,Kelly HK.Predictors of tumor progression during neoadjuvant chemotherapy on breast cancer[J].J Clin Oncol,2009,27(15 Suppl):a603.
4Mathew J,Asgeirsson KS,Cheung KL,et al.Neoadjuvant chemotherapy for locally advanced breast cancer:A review of the literature and future directions[J].European Journal of Surgical Oncology,2009,35(2):113-122.
5Gunter von M,Sibylle L,Manfred K.Neoadjuvantbreast cancer therapy:the German experience[J].European Journal of Cancer Supplements,2008,6(2):4-9.
6Citron M.A randomized trial of dose-dense vs conventionally scheduled and sequential vs concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer[J].J Clin Onco,2003,21(8):1431-1439.
